Nanoparticles to carry brain tumor drugs across the blood–brain barrier
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics
This project aims to use specially designed nanoparticles to deliver cancer medicines into the brains of people with glioblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11319802 on NIH RePORTER |
What this research studies
I would hear that researchers are building tiny targeted particles with two parts: one to cross the blood–brain barrier and one to release medicine inside the tumor. They plan to load these particles with drugs that work against STAT3 and other chemotherapies that normally can’t get into the brain. The team will test the particles in laboratory and animal models to see if they reach brain tumors and shrink them. Promising results would support moving toward human clinical trials in the future.
Who could benefit from this research
Good fit: People with glioblastoma, especially those whose tumors are resistant to standard surgery, radiation, and temozolomide, would be the likely candidates for future trials.
Not a fit: People without brain tumors or those who cannot receive systemic therapy would not be expected to benefit from this approach.
Why it matters
Potential benefit: If successful, this could allow more effective, less invasive delivery of anti-tumor drugs to brain tumors and may improve tumor control and survival.
How similar studies have performed: Related nanoparticle methods have shown promise in lab and animal studies, but reliably delivering drugs across the human blood–brain barrier remains largely unproven and this specific bi‑compartmental approach is relatively novel.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Lahann, Joerg — University of Michigan at Ann Arbor
- Study coordinator: Lahann, Joerg
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.